Prescient Therapeutics (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in the US.
The company said the new results demonstrate the capabilities of OmniCAR to deliver next-generation cell therapies that are controllable and able to target multiple cancer antigens.
OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
According to Prescient’s director of scientific affairs, Dr Rebecca Lim, “Critical features of OmniCAR have been tested in recent months and the data continue to be extremely positive. Our most recent work conducted in collaboration with the Peter MacCallum Cancer Centre showed that OmniCAR-T cells begin antigen-directed killing of tumour cells in vitro as soon as they are armed.
"The team also showed that OmniCAR-T cells could be re-armed and continue to kill tumour cells without loss of cytotoxicity. Excitingly, we saw for the first time the real-time ‘switchability’ of the OmniCAR system where the tumour killing ability of the OmniCAR-T cells could be redirected towards a different antigen through the addition of a different binder. These early wins are extremely encouraging, and we look forward to the next phase of pre-clinical testing where the OmniCAR technology will be put through its paces using gold-standard cancer models.”
Prescient managing director and CEO, Steven Yatomi-Clarke said, "We look forward to presenting this exciting data at Cell and Gene Meeting on the Mesa this week and next, where Prescient has the opportunity to share the features of OmniCAR with prominent companies in the field.
"It is very pleasing to see a large body of work accomplished successfully so quickly and is a credit to the Prescient team and the incredible collaborators at Peter MacCallum Cancer Centre. Importantly, none of these tests have even been optimised, so we have yet to see the true limits of this technology. OmniCAR is proving to be a predictable and powerful system to work with. We look forward to sharing updates as our programs progress.”
